Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer

Shinzaburo Noguchi 1 · Hee Jeong Kim 2 · Anita Jesena 3 · Vani Parmar 4 · Nobuaki Sato 5 · Hwei-Chung Wang 6 · Santi Lokejaroenlarb 7 · Jofel Isidro 8 · Ku Sang Kim 9 · Yohji Itoh 10 · Eisei Shin 10

Received: 22 May 2015 / Accepted: 20 August 2015 / Published online: 9 September 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Background Monthly goserelin 3.6 mg dosing suppresses estradiol (E2) production and has proven efficacy in pre-menopausal women with estrogen receptor (ER)-positive breast cancer. This non-inferiority study evaluated the efficacy and safety of 3-monthly goserelin 10.8 mg compared with monthly goserelin 3.6 mg.

Methods This was a Phase 3, open-label, multicenter trial. Pre-menopausal women with ER-positive advanced breast cancer were randomized to 3-monthly goserelin 10.8 mg or monthly goserelin 3.6 mg; all patients received concomitant tamoxifen (20 mg daily). The primary endpoint was progression-free survival (PFS) rate at 24 weeks; non-inferiority was to be confirmed if the entire 95 % confidence interval (CI) for the treatment difference was above −17.5 %. Secondary endpoints included objective response rate (ORR), serum E2 levels, safety, and tolerability.

Results In total, 222 patients were randomized (goserelin 10.8 mg, n = 109; goserelin 3.6 mg, n = 113). PFS rate at week 24 was 61.5 % (goserelin 10.8 mg) and 60.2 % (goserelin 3.6 mg); treatment difference (95 % CI) was 1.3 % (−11.4, 13.9), confirming non-inferiority of goserelin 10.8 mg compared with goserelin 3.6 mg. ORR was 23.9 % (goserelin 10.8 mg) and 26.9 % (goserelin 3.6 mg); treatment difference (95 % CI) was −3.0 % (−15.5, 9.7). At week 24, mean serum E2 concentrations were similar in the goserelin 10.8 mg and goserelin 3.6 mg groups (20.3 pg/mL and 24.8 pg/mL, respectively).

Conclusion A regimen of 3-monthly goserelin 10.8 mg demonstrated non-inferiority compared with monthly goserelin 3.6 mg for PFS rate at 24 weeks, with similar pharmacodynamic and safety profiles, in pre-menopausal women with ER-positive breast cancer.

Keywords Goserelin · Pre-menopausal · Advanced breast cancer · Progression-free survival · Estrogen receptor

Introduction

Approximately two-thirds of patients diagnosed with breast cancer have hormone-receptor–positive [estrogen receptor (ER) and/or progesterone receptor (PgR)] tumors and are suitable candidates for endocrine therapy [1]. Estradiol (E2) is the main source of estrogen in pre-menopausal women and is synthesized and released from the ovaries under the control of luteinising hormone-releasing
hormone (LHRH) [2]. Ovarian ablation or suppression can, therefore, be used to impede E2 production, thereby inhibiting estrogen-dependent tumor growth in pre-menopausal patients with ER-positive breast cancer. Goserelin (Zoladex®, AstraZeneca) is an LHRH agonist that reduces ovarian E2 production, and, unlike ovarian ablation, its effects are reversible. Goserelin has demonstrated efficacy for the adjuvant treatment of pre-menopausal women with ER-positive breast cancer, with equivalent disease-free survival to cytotoxic chemotherapy [3], and a more favorable safety profile [4].

The efficacy, safety, and endocrine effects of monthly goserelin 3.6 mg, with or without concomitant tamoxifen, in pre- and peri-menopausal women with ER-positive advanced breast cancer are well documented [5–7]. Furthermore, the combination of an LHRH agonist with tamoxifen has been shown to be more effective than each treatment alone [8, 9], and this is now a standard treatment choice in these patients [10, 11].

Goserelin 10.8 mg administered once every 3 months is already approved in many countries for the treatment of prostate cancer [12–14], and this formulation may also provide a more convenient treatment option for breast cancer patients due to its less frequent administration schedule. A recent Phase 2 clinical study found that 3-monthly goserelin 10.8 mg was non-inferior to monthly goserelin 3.6 mg for the primary endpoint of serum E2 suppression in pre-menopausal patients with ER-positive early breast cancer, with no difference in safety profile [15].

The current non-inferiority study was designed to evaluate the efficacy and safety of 3-monthly goserelin 10.8 mg versus monthly goserelin 3.6 mg in pre-menopausal women with ER-positive advanced breast cancer.

**Patients and methods**

**Study design and patients**

This was a Phase 3, open-label, randomized, parallel group, multicenter trial designed to evaluate whether 3-monthly goserelin 10.8 mg is non-inferior to monthly goserelin 3.6 mg in pre-menopausal women with ER-positive advanced breast cancer by assessment of progression-free survival (PFS) rate at 24 weeks (ClinicalTrials.gov identifier: NCT01073865).

Eligible patients were randomized 1:1 to receive a goserelin 10.8 mg subcutaneous (sc) depot injection every 12 weeks (±7 days; 3-monthly goserelin 10.8 mg treatment group) or a goserelin 3.6 mg sc depot injection every 4 weeks (±7 days; monthly goserelin 3.6 mg treatment group). All patients also received a daily oral dose of tamoxifen (20 mg) (Fig. 1). The study population comprised pre-menopausal women aged ≥20 years with histologically/cytologically confirmed, hormone-sensitive breast cancer; ≥1 lesion that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI, or plain X-ray according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 [16]; and a World Health Organization performance status of 0, 1, or 2. Pre-menopausal status was defined as experiencing menses within 1 year prior to randomization, and serum concentrations for E2 ≥10 pg/mL and follicle-stimulating hormone (FSH) ≤30 mIU/mL within 4 weeks prior to randomization (for patients who had undergone a hysterectomy, only the latter criterion was required).

Patients were excluded from the study if they had received: hormonal therapies within the previous 24 weeks (or at any point for treatment of advanced breast cancer);
LHRH agonist therapy within the previous 48 weeks; radiotherapy or trastuzumab/lapatinib treatment for early breast cancer within the previous 4 weeks (or at any point for treatment of advanced breast cancer); chemotherapy within the previous 4 weeks or for advanced breast cancer (except first-line chemotherapy with the presence of menses and no evidence of disease progression). Additional exclusion criteria included: relapse during or within 48 weeks of adjuvant hormonal therapy, or during or within 24 weeks of adjuvant chemotherapy; previous non-breast cancer malignancy (other than controlled basal/squamous carcinoma or cancer of the cervix); life-threatening metastatic disease; abnormal laboratory tests results; a history of disseminated intravascular coagulation or long-term anticoagulant therapy (other than antiplatelet or warfarin). Patients could not participate if they were likely to be hypersensitive to study treatments, unwilling/unable to stop taking drugs known to affect sex hormone status, were pregnant/breastfeeding, had received an unapproved drug in the previous 12 weeks, were unlikely to comply with study requirements, or had any concomitant disease that would place them at risk or may confound the results of the study. All patients provided written informed consent.

Patients continued study treatment for 24 weeks or until any of the criteria for discontinuation were met (including voluntary discontinuation, safety issues, medication non-compliance, pregnancy, disease progression, or death). Final assessment of efficacy was completed at the time of disease progression or at week 24, whichever was sooner.

The study protocol was approved by the relevant ethics committees and institutional review boards and was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation/Good Clinical Practice, the applicable local regulatory requirements at each study center, and the AstraZeneca policy on Bioethics. All patients provided written informed consent.

**Efficacy endpoints**

The primary endpoint was PFS rate at 24 weeks, used to assess the non-inferiority of 3-monthly goserelin 10.8 mg versus monthly goserelin 3.6 mg. Secondary efficacy endpoints included objective response rate (ORR) and serum E2 concentrations. Efficacy assessments were performed at weeks 12 and 24.

PFS rate, defined as the proportion of patients who were progression-free, was analyzed at 24 weeks. Analysis of ORR, defined as the proportion of patients with a best response of complete or partial response, was determined at each site by RECIST criteria, and assessed in patients who had measurable disease at baseline (e.g., patients with bone metastases). A sub-analysis of efficacy endpoints was carried out to determine if there were differences in treatment response between Japanese and non-Japanese patients. Pharmacodynamic effects were evaluated by recording serum E2 in both treatment groups at baseline and at 12 and 24 weeks. A central laboratory service (Covance Central Laboratory Services) performed chemiluminescent enzyme immunoassay to determine E2 (ADVIA centaur estradiol-6 III, Siemens Medical Solutions Diagnostics, NY, USA) and FSH (Access hFSH, Beckman Coulter Inc., CA, USA) concentrations. The lower limit of quantification (LLOQ) was 18.07 pg/mL for E2, and 0.6 mIU/mL for FSH.

**Safety and tolerability**

Assessments of adverse events (AEs) and serious AEs (SAEs) were carried out to compare the safety and tolerability profiles of 3-monthly goserelin 10.8 mg and monthly goserelin 3.6 mg. Final assessment of safety was carried out at week 24 (if treatment was discontinued prior to week 24), 12 weeks after the final dose of goserelin 10.8 mg, or 4 weeks after the final dose of goserelin 3.6 mg. The safety analysis was conducted in all patients who received ≥1 treatment after randomization. A sub-analysis of the incidence of AEs/SAEs was also conducted in Japanese and non-Japanese patients. SAEs were classified by the Medical Dictionary for Regulatory Activities preferred term and system organ class.

**Statistical analysis**

Based on a meta-analysis by Klijn et al., the proportion of patients who had not progressed during the first 24 weeks of treatment with the combination of goserelin 3.6 mg and tamoxifen was estimated to be approximately 70% [9]. Therefore, a sample size of 216 patients (108 per group) was planned to demonstrate non-inferiority based on a prespecified margin of −17.5 % between treatment groups (deemed clinically acceptable) using a 2-sided 95 % confidence interval (CI) with 80 % power. The non-inferiority margin was chosen based on an admissible 75 % relative efficacy of the 3-monthly goserelin 10.8 mg treatment regimen versus the monthly goserelin 3.6 mg treatment regimen.

Two-sided 95 % CIs were calculated using the score based method recommended by Newcombe and Altman [17]. For the primary endpoint, non-inferiority of the 3-monthly goserelin 10.8 mg treatment regimen versus the monthly goserelin 3.6 mg treatment regimen was to be concluded if the lower limit of the 95 % CI for the difference was greater than −17.5 %. This non-inferiority limit was only applicable to the primary endpoint of PFS at 24 weeks in the overall population; no non-inferiority
testing was carried out for other endpoints or subgroups. ORRs at 24 weeks were determined for each treatment, and the difference and 95% CI numerically compared. Mean serum E2 concentrations were compared using analysis of covariance (ANCOVA), with treatment group, baseline serum E2 concentrations, and ethnicity (Japanese versus non-Japanese) as covariates. Clinical laboratory data were summarized by treatment group using descriptive statistics.

Results

Patients

This study was conducted at 58 centers: India (15 centers), Japan (19 centers), Korea (4 centers), the Philippines (7 centers), Thailand (8 centers), and Taiwan (5 centers). In total, 222 patients were randomized to receive 3-monthly goserelin 10.8 mg (n = 109) or monthly goserelin 3.6 mg (n = 113). Of these patients, 30.6% (n = 68) discontinued from the study [25.7% (n = 28) in the goserelin 10.8 mg group; 35.4% (n = 40) in the goserelin 3.6 mg group] with the most common reason for withdrawal being disease progression (Fig. 2).

All patients were ER-positive, and the majority of patients were both ER- and PgR-positive [82.6% (n = 90) in the goserelin 10.8 mg group; 77.9% (n = 88) in the goserelin 3.6 mg group]. The majority of patients were human epidermal growth factor receptor 2 negative [68.8% (n = 65) in the goserelin 10.8 mg group; 74.3% (n = 84) in the goserelin 3.6 mg group]. Patient demographics and baseline characteristics were well balanced between the treatment groups and also between the treatment groups in the Japanese and non-Japanese subgroups (Table 1).

Efficacy

In total, 61.5% (n = 67) of patients in the goserelin 10.8 mg group and 60.2% (n = 68) of patients in the goserelin 3.6 mg group were progression-free at 24 weeks (treatment difference: 1.3; 95% CI −11.4, 13.9). Since the lower 95% CI was above the pre-defined margin of −17.5%, 3-monthly goserelin 10.8 mg met the criteria for non-inferiority compared with monthly goserelin 3.6 mg (Fig. 3).

In the Japanese population, 72.4% (n = 21/29) of patients in the goserelin 10.8 mg group and 80.0% (n = 24/30) of patients in the goserelin 3.6 mg group were progression-free at 24 weeks (treatment difference: −7.6; 95% CI −28.5, 14.0). In the non-Japanese population, 57.5% (n = 46/80) of patients in the goserelin 10.8 mg group and 53.0% (n = 44/83) of patients in the goserelin 3.6 mg group were progression-free at 24 weeks (treatment difference: 4.5; 95% CI −10.6, 19.4).

At 24 weeks, the ORR in patients with measurable disease at baseline was 23.9% (n = 21/88) in the goserelin 10.8 mg group and 26.9% (n = 25/93) in the goserelin 3.6 mg group (treatment difference: −3.0%; 95% CI −15.5, 9.7; Table 2). In Japanese patients, ORR was 25.9% (n = 7/27) in the goserelin 10.8 mg group and 37.0% (n = 10/27) in the goserelin 3.6 mg group (treatment difference: −11.1%; 95% CI −33.8, 13.2). In non-Japanese patients the ORR was 23.0% (n = 14/61) in the goserelin 10.8 mg group and 22.7% (n = 15/66) in the goserelin 3.6 mg group (treatment difference: 0.2%; 95% CI −14.2, 14.9).

Pharmacodynamics

Mean (standard deviation) serum E2 concentrations throughout the study period are presented in Fig. 4. At week 24, serum E2 concentrations were 20.3 (12.3) pg/mL and 24.8 (28.1) pg/mL in the goserelin 10.8 mg and goserelin 3.6 mg groups, respectively.

Safety and tolerability

A total of 143 of 221 (64.7%) patients reported ≥1 AE [65.7% (n = 71) of patients in the goserelin 10.8 mg group and 63.7% of patients (n = 72) in the goserelin 3.6 mg group]. The most common AEs are shown in Table 3; the majority of AEs were mild or moderate (Grade 2 or lower).

A total of 12 patients reported a SAE (4 patients in the goserelin 10.8 mg group and 8 patients in the goserelin 3.6 mg group). The incidence of SAEs was 3.7% in the goserelin 10.8 mg group and 7.1% in the goserelin 3.6 mg group. A total of 7 patients died in the study (4 patients in goserelin 10.8 mg group, 3 patients in goserelin 3.6 mg group). Three patients in the goserelin 10.8 mg group and 2 patients in the goserelin 3.6 mg group died due to disease progression. One patient in each group died following an AE. One patient was a 23-year-old female who had breast lumpectomy approximately 4 months prior to receiving goserelin 10.8 mg and had received zoledronic acid due to bone metastasis with no other prior medications or radiotherapy. This patient had been judged to have stable disease 2 months after their first depot 10.8 mg goserelin dose; 2 months after the second dose this patient reported chest pain, diarrhea and vomiting, and died. The other patient was a 34-year-old female who had previously had modified radical mastectomy of the right breast and had received adjuvant tamoxifen and chemotherapy (5-fluorouracil, epirubicin and cyclophosphamide) approximately 2.5 years prior to receiving goserelin.
Approximately 3 months after the first depot goserelin 3.6 mg dose, this patient had been judged to have partial disease response. Approximately 2 weeks after the 6th dose, the patient developed dyspnea and pyrexia and died due to dyspnea. Neither of these deaths were judged by the investigators to be related to study treatment.

In Japanese patients, the incidence of AEs was 96.6 % (n = 28/29) in the goserelin 10.8 mg group and 83.3 % (n = 25/30) in the goserelin 3.6 mg group. Two SAEs occurred among Japanese patients, both in the goserelin 3.6 mg group. In non-Japanese patients, the incidence of AEs was 54.4 % (n = 43/79) in the goserelin 10.8 mg group and 56.6 % (n = 47/83) in the goserelin 3.6 mg group. SAEs were experienced by 5.1 % (n = 4/79) of non-Japanese patients in the goserelin 10.8 mg group and 7.2 % (n = 6/83) in the goserelin 3.6 mg group.

**Discussion**

This randomized, open-label, Phase 3 controlled trial compared PFS rate in pre-menopausal women with ER-positive advanced breast cancer after 24 weeks of treatment with 3-monthly goserelin 10.8 mg or monthly goserelin 3.6 mg. The result of the primary efficacy analysis found that goserelin 10.8 mg demonstrated non-
inferiority to goserelin 3.6 mg. Secondary outcomes, such as ORR, were also similar between both treatment groups, suggesting that the similarities seen between the 2 dosing regimens are consistent across several efficacy parameters. PFS rate and ORR were both numerically higher in the Japanese subgroup; however, the sample sizes for these analyses were too small to enable definitive conclusions to be drawn.

Results from the present study demonstrate that the goserelin 10.8 mg group elicited levels of serum E2 suppression at week 24 that were comparable with those in the goserelin 3.6 mg group. These results are similar to those reported in another clinical study comparing 3-monthly goserelin 10.8 mg with monthly goserelin 3.6 mg treatment in pre-menopausal women with early-stage breast cancer, in which serum E2 concentrations were also suppressed to post-menopausal levels (≤30 pg/mL) in both treatment groups [15]. There were no obvious differences in suppression of serum E2 concentration between Japanese and non-Japanese patients. Goserelin 10.8 mg was well tolerated and showed a similar safety and tolerability profile to goserelin 3.6 mg. Treatment-related AEs reported in this study were consistent with the established safety profile for goserelin 10.8 mg (given for the treatment of

| Patient demographics and baseline characteristics | All patients | Japanese patients | Non-Japanese patients | Total |
|-------------------------------------------------|-------------|-------------------|-----------------------|-------|
| Goserelin 10.8 mg (n = 109) | Goserelin 3.6 mg (n = 113) | Goserelin 10.8 mg (n = 29) | Goserelin 3.6 mg (n = 30) | Goserelin 10.8 mg (n = 80) | Goserelin 3.6 mg (n = 83) | Total (n = 222) |
| Median age, years (range) | 41.0 (23–53) | 45.0 (27–53) | 40.0 (23–53) | 40.0 (27–50) | 42.0 (23–54) |
| Age group, n (%) | | | | | |
| <40 | 42 (38.5) | 4 (13.8) | 38 (47.5) | 38 (45.8) | 88 (39.6) |
| ≥40 | 67 (61.5) | 25 (86.2) | 42 (52.5) | 45 (54.2) | 134 (60.4) |
| Ethnicity, n (%) | | | | | |
| Asian (non-Chinese/Japanese) | 73 (67.0) | 0 | 73 (91.3) | 147 (66.2) |
| Chinese | 7 (6.4) | 0 | 7 (8.8) | 16 (7.2) |
| Japanese | 29 (26.6) | 29 (100.0) | 0 | 59 (26.6) |
| Previous type of therapy, n (%) | | | | | |
| Radiotherapy | 19 (17.4) | 4 (13.8) | 15 (18.8) | 36 (16.2) |
| Chemotherapy | 29 (26.6) | 3 (10.3) | 26 (32.5) | 56 (25.2) |
| Other systemic anticancer therapy | 1 (0.9) | 0 | 1 (1.3) | 1 (0.5) |
| Immunotherapy | 0 | 0 | 0 | 0 |
| Hormonal therapy | 9 (8.3) | 4 (13.8) | 5 (6.3) | 19 (8.6) |
| WHO performance status, n (%) | | | | | |
| 0 | 83 (76.1) | 22 (75.9) | 61 (76.3) | 175 (78.8) |
| 1 | 26 (23.9) | 7 (24.1) | 19 (23.8) | 44 (19.8) |
| 2 | 0 | 0 | 0 | 3 (1.4) |
| Disease stage, n (%) | | | | | |
| Locally advanced only | 9 (8.3) | 3 (10.3) | 6 (7.5) | 25 (11.3) |
| Metastatic | 100 (91.7) | 26 (86.7) | 74 (92.5) | 197 (88.7) |
| Measurable disease, n (%) | | | | | |
| Yes | 88 (80.7) | 27 (93.1) | 61 (76.3) | 181 (81.5) |
| No | 21 (19.3) | 2 (6.9) | 19 (23.8) | 41 (18.5) |

WHO World Health Organization

a Details for previous therapies for one patient were not recorded in the database
Fig. 3  Progression-free survival at week 24: non-inferiority analysis. CI confidence interval, PFS progression-free survival

Table 2  Best objective response at week 24

|                        | Goserelin 10.8 mg (n = 88) | Goserelin 3.6 mg (n = 93) |
|------------------------|----------------------------|---------------------------|
| Complete response, n (%)| 1 (1.1)                    | 0                         |
| Partial response, n (%) | 20 (22.7)                  | 25 (26.9)                 |
| ORR, n (%)              | 21 (23.9)                  | 25 (26.9)                 |
| Treatment difference, % (95 % CI) | -3.0 (-15.5, 9.7)      |                           |

CI confidence interval, ORR objective response rate

* Included only patients who had measurable disease at baseline

Fig. 4  Serum E2 concentration at baseline, 12 weeks and 24 weeks. E2 estradiol, SD standard deviation

|                        | Goserelin 10.8 mg | Goserelin 3.6 mg |
|------------------------|-------------------|------------------|
| Mean pg/mL (SD)        | 132.6 (123.2)     | 116.3 (122.1)    |
| n = 107                |                   | n = 110          |
| Mean pg/mL (SD)        | 26.3 (62.1)       | 25.4 (41.3)      |
| n = 81                 |                   | n = 77           |
| Mean pg/mL (SD)        | 20.3 (12.3)       | 24.8 (28.1)      |
| n = 74                 |                   | n = 70           |
prostate cancer) and goserelin 3.6 mg in female patients. The incidence of AEs appeared to be higher in Japanese than in non-Japanese patients; the reason for this is unclear. However, the incidence of SAEs was similarly low in both Japanese and non-Japanese patients. In addition, there were no clear differences in the incidence of AEs between goserelin 10.8 mg and goserelin 3.6 mg treatment groups when assessing the Japanese and non-Japanese subgroups.

Anecdotal evidence suggests that monthly sc depot injections are uncomfortable for the patient [18]. A dosing regimen of 3-monthly goserelin 10.8 mg offers an alternative dosing schedule that may be more convenient for some patients, thus, potentially helping to improve compliance. Moreover, a 3-month dosing regimen with fewer clinic visits could help to reduce clinician burden and associated healthcare costs.

Potential limitations of the study include the open-label design and the relatively short study length. The expected difficulty of enrolling patients into the study from a limited population pool (i.e., pre-menopausal patients with advanced breast cancer) was taken into consideration when designing the study. As goserelin was used in combination with tamoxifen in both treatment groups, it was also not possible to fully determine the effect of the individual treatments (tamoxifen or goserelin) used in the study. However, this combination therapy approach was in line with current clinical practice guidelines [10, 19].

In conclusion, this study demonstrated that 3-monthly goserelin 10.8 mg is non-inferior to monthly goserelin 3.6 mg in pre-menopausal women with ER-positive advanced breast cancer by assessment of PFS rate at 24 weeks. As such, this formulation may represent an alternative and more convenient treatment option for pre-menopausal women with ER-positive advanced breast cancer.

Acknowledgments This work was sponsored by AstraZeneca, who provided support for the conduct of the study, data collection and

| Table 3 Common AEs occurring in ≥3 % of patients |
|-----------------------------------------------|
| AE by system organ class | Goserelin 10.8 mg (n = 108) | Goserelin 3.6 mg (n = 113) | Total (n = 221) |
| Patient with any AE, n (%) | 71 (65.7) | 72 (63.7) | 143 (64.7) |
| Vascular disorders, n (%) | | | |
| Hot flush | 15 (13.9) | 22 (19.5) | 37 (16.7) |
| Infections and infestations, n (%) | | | |
| Nasopharyngitis | 13 (12.0) | 9 (8.0) | 22 (10.0) |
| Musculoskeletal and connective tissue disorders, n (%) | | | |
| Back pain | 5 (4.6) | 9 (8.0) | 14 (6.3) |
| Pain in extremity | 3 (2.8) | 5 (4.4) | 8 (3.6) |
| Nervous system disorders, n (%) | | | |
| Headache | 7 (6.5) | 7 (6.2) | 14 (6.3) |
| Gastrointestinal disorders, n (%) | | | |
| Nausea | 2 (1.9) | 9 (8.0) | 11 (5.0) |
| Constipation | 4 (3.7) | 5 (4.4) | 9 (4.1) |
| Vomiting | 4 (3.7) | 3 (2.7) | 7 (3.2) |
| Abdominal pain | 1 (0.9) | 4 (3.5) | 5 (2.3) |
| General disorders and administration site conditions, n (%) | | | |
| Pyrexia | 2 (1.9) | 7 (6.2) | 9 (4.1) |
| Fatigue | 1 (0.9) | 4 (3.5) | 5 (2.3) |
| Psychiatric disorders, n (%) | | | |
| Insomnia | 3 (2.8) | 6 (5.3) | 9 (4.1) |
| Respiratory, thoracic and mediastinal disorders, n (%) | | | |
| Cough | 3 (2.8) | 4 (3.5) | 7 (3.2) |
| Blood and lymphatic system disorders, n (%) | | | |
| Anemia | 4 (3.7) | 4 (3.5) | 8 (3.6) |

AE adverse event
project management. We thank all the patients and investigators who participated in the study. We also thank Jennifer Higgison, PhD, and Martin Bell, PhD, from Complete Medical Communications for providing medical writing support funded by AstraZeneca.

Compliance with ethical standards

Conflicts of interest Y. Itoh and E. Shin are employees of, and hold stock in, AstraZeneca. S. Noguchi has received honoraria from AstraZeneca and funding for research from AstraZeneca and Takeda. The remaining authors have no conflicts of interest to declare.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol. 2003;21:28–34.
2. Hilakivi-Clarke L, Cabanes A, Olivo S, Kerr L, Bouker KB, Clarke R. Do estrogens always increase breast cancer risk? J Steroid Biochem Mol Biol. 2002;80:163–74.
3. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, De Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20:4628–35.
4. Jakesz R, Hausmaninger H, Kubista E, Grant M, Menzel C, Bauerhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasyw W, Fridrik M, Steger G, Wette V, Samonigg H. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20:4621–7.
5. Boccardo F, Rubagotti A, Ferrotta A, Amoroso D, Balestrero M, De Matteis A. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentre Italian study. Ann Oncol. 1994;5:337–42.
6. Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Jänicke F, Nordenskold B, Forbes JF. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 1995;31A:137–42.
7. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert NJ, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998;16:994–9.
8. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92:903–11.
9. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, Combined Hormone Trialists Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343–53.
10. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cuter T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871–88.
11. Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL, Smith IE. UK guidance document: treatment of metastatic breast cancer. Clin Oncol (R Coll Radiol). 2012;24:169–76.
12. AstraZeneca: Zoladex® LA 10.8 mg Implant—Prescribing Information. 2013.
13. Dijkstra GA, Debruyne FM, Fernandez del Moral P, Plasman JW, Hoeafakker JW, Iedema JG, Sykes M. A phase III randomised trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group. Eur Urol. 1994;26(Suppl 1):1–2.
14. Dijkstra GA, Debruyne FM, Fernandez del Moral P, Plasman JW, Hoeafakker JW, Iedema JG, Sykes M. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. Eur Urol. 1995;27:43–6.
15. Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, Takei H, Yanagita Y, Noguchi S. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2011;126:443–51.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
17. Newcomer RN, Altman DG: Proportions and their differences. 2nd ed. 2000.
18. Lette J. A simple step to improve patient adherence with Zoladex. Clin J Oncol Nurs. 2008;12:181.
19. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solkky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2014;32:2255–69.